Head-to-head evidence
amiselimod vs tamuzimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
amiselimod
Developed by Bausch Health under a licence from Mitsubishi Tanabe Pharma
NCT04857112 · Phase 2 · completed
This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
tamuzimod
Developed by Eli Lilly
NCT05156125 · Phase 2 · terminated
This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · tamuzimod's landscape